Navigation Links
Gardasil, a cervical cancer vaccine, hits the market

This is indeed an important milestone in the development of strategies to combat cervical abnormalities; the worlds first ever vaccine for cervical cancer, named Gardasil, has// made it to the market.

A feather in the cap of Professor Frazer, a scientist in Queens land and the brain behind this vaccine, who has relentlessly worked on this working on it since 1990, is all set to administer the inaugural shot. This vaccine is powerful in containing the spread of sexually transmitted human papilloma virus (HPV), the main reason behind cervical cancer. Further this vaccine will also protect against HPV, which causes genital warts.

An ecstatic Fraser said 'The vaccine will be available from today so if someone turns up at the pharmacy with a script they'll be able to get it. I know there's a large number of people waiting for this particular day to happen because I get phoned up regularly and asked when it was going to occur.'

The Therapeutic Goods Administration (TGA) has permitted the use of this vaccine for boys aged nine to 15 and girls aged nine to 26. This vaccine holds a world of promise, based on the results of the clinical trials, where nearly 20,000 women received 100% protection from cervical cancer and 99% insulation from genital warts.
'"/>




Page: 1

Related medicine news :

1. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
2. Virus connection to cervical injury
3. Test for prenatal chromosomal abnormalities using cervical swab
4. Two New Human Papilloma virus (HPV) vaccines to prevent cervical cancer
5. Gardasil vaccine for cervical cancer
6. Two screen test and treat screening for cervical cancer
7. Religious groups overcome objections to cervical cancer vaccines
8. Merck, ICMR to conduct joint trials on cervical cancer vaccine
9. Economic and Ethical disparities hinder cervical cancer screening
10. Conventional pap smears techniques to detect cervical cancer are here to stay
11. The need to revamp cervical cancer prevention programs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: